In self pay markets, patients feel every euro or dollar. So rather than doing too many tactics, the teams that win focus on and even over commit to what matters most, from market development and disease awareness to the specific journeys and influencers that shape willingness to pay. Things which don’t matter are not deprioritized they are sacrificed.
As many of us have observed payment models continue to change and fragment. In self pay and fast evolving employer and payer models, patients feel every euro or dollar – and employers and payers are constantly recalibrating what they will fund.
The most effective launch teams address two simple questions early on as part of launch planning in phase 2:
“What launch type do we really have?”
“What does this payment model make non negotiable?”
The answers to those two questions should shape the value proposition, channels, evidence strategy and KPIs – and they differ markedly between self pay and employer or payer covered models.
Teams who behave as if payment models are a detail, not a design principle, use the same governance, KPIs, field footprint and launch processes regardless of who is actually paying. The result is over engineered plans, over stretched teams and underwhelming uptake. When you look at launches through a payment model lens, 2 realities stand out.
Self pay markets are brutally direct. The patient is not just the end user; in many cases they are the buyer. They make decisions quickly, compare you against other consumer purchases, and feel every unit of currency they spend. If the perceived benefit, value, convenience and practical access are not obvious and immediate, they hesitate – or walk away.
Employer and payer covered markets are structurally different. Here, the “customer” is an institution. Uptake depends on coverage decisions, formulary placement, prior authorisation criteria, utilisation management and the employer’s or payer’s view of budget impact and outcomes. Even when the patient contribution is non trivial, the decisive friction is often upstream – in contracting, benefit design and economic proof.
When self pay and employer/payer launches are run through the same governance and KPI dashboard, typically: what's easy rather than what matters get measured (e.g. call volumes instead of conversion or coverage); field forces are too thinly across diverse customers, instead of building depth with the ones that control access or willingness to pay and over invest in low impact activity (e.g. broad awareness) while under investing in the specific journey steps where patients or payers say “no”.
It is critical to define and address the requirements of the dominant payment models in early launch planning, which starts in phase 1.
Many self pay launches behave far more like consumer commerce than traditional pharma. The buyer is the end user. Decisions are made quickly, often emotionally. Benefit, price, trust and convenience carry disproportionate weight. In that context, the traditional “awareness → education → HCP recommendation → prescription → fulfilment” lens is too slow and too vague. A more honest description looks like a consumer funnel:
Awareness → Interest → Eligibility/fit check → Decision to pay → First use → Repeat use.
That has concrete implications.
Simple, consumer style pricing architecture. Complex co pay tables and opaque assistance programmes don’t work. Patients want to know, quickly, “What will this cost me – now and over time?” Tiered pricing, starter offers, membership models and subscription like replenishment feel familiar because they mirror how people pay in other parts of their lives.
Patient facing value propositions, not repurposed HCP decks. They respond to clear, credible narratives about what matter to them: function, confidence, relationships, daily life. The most effective launches translate clinical and economic value into language and proof points that a lay person can understand and repeat.
Digital journeys designed for conversion, not just education. High performing launches design journeys with conversion in mind: from symptom or disease awareness through eligibility checks, guidance on talking to an HCP, to payment and fulfilment. They test and optimise each micro step.
Relentless friction reduction. Small frictions matter: a confusing landing page, hidden fees, slow appointment access, unclear shipping timelines. The bar is set by e commerce, not by other pharma brands. That often means:
Seamless digital onboarding and eligibility screening
Transparent, up front pricing
Home delivery as standard, not as an optional extra
Proactive reminders and nudges for refills or follow up appointments
Rapid access to human support when questions or anxiety arise
In many self-pay cases, you are operating in a new asset / new customer group, where the real work is market development – building disease awareness, reshaping pathways of care and designing the ecosystem that makes it realistic for patients to pay.
Obesity
In many markets, anti obesity medicines are still largely self pay. Patients compare the cost not only with other treatments, but with gym memberships, diets and consumer wellness products. Launches that succeed invest in digital tools for self assessment, clear messaging on health and quality of life benefits, and simple subscription models with integrated coaching or support – not just a price list and HCP detailing. So you can imagine the impact of generics could be expected to bit and fast!
Fertility and sexual health
Here, the emotional stakes are high and the willingness to pay can be significant, but trust and discretion are critical. Successful self pay launches blend reassuring, stigma reducing content with highly private, convenient access pathways – think home sampling, telehealth consultations and discreet delivery – and pricing that is predictable across what can be a long and uncertain journey.
The most effective teams start early in phase 2 and tailor their launch framework to create a plan service of a self-pay launch and ask a small set of grounding questions in each market:
What is the dominant payment model in the segments we care about most? Not just today, but over the launch horizon. Where is the volume and value likely to sit?
Where are the biggest frictions to pay and access in that model? Is it awareness, trust, perceived value, price, or practical access?
Do our value propositions, channels and KPIs line up with those levers – or with our internal habits? If dashboards still prioritise call volumes when the real constraint is coverage, or website traffic when the real issue is conversion at payment, there is a misalignment problem
Are we organised for B2C, B2B – or both? Where launches sit across self pay and covered segments explicit choices need to be made about who leads on consumer grade experience design vs account strategy, how you govern trade offs, and how you avoid trying to “do everything for everyone”.
When teams tailor their launch framework to create a launch plan working through these questions honestly, they usually move from generic plans to sharply focused launch designs – ones that respect the realities of who pays, how they decide and what they will need to see to say “yes”.
Building a modern, successful launch capability is a continuous journey. This article is the last in a five-part series exploring the realities of pharma commercialization today. Read the rest of the series here: